Determination of the Nature of the Endogenous Ligand of TREM-1 and Its Use as a New Diagnostic Biomarker in Sepsis

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01903668

Enrollment

Registered

2013-07-19

Start date

2012-04-30

Completion date

Unknown

Last updated

2013-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

Step 1: Identification and characterisation of the TREM1L protein from samples already available characterised at the hospital Central of Nancy Step 2: Study of the isoforms of TREM1L in correlation with the prognosis of sepsis, Step 3: implementation of assay methods for TREM1L (ELISA or SUPRA MS) Step 4: Validation of assays for TREM1L and its isoforms in a larger number of subjects (inclusion of samples from Dijon CHU and Besançon CHU)

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients hospitalised in a Medical Intensive Care unit whatever the reason * written informed consent obtained

Exclusion criteria

* patients less than 18 years old or under guardianship, persons without national health insurance.

Design outcomes

Primary

Measure	Time frame
plasma concentrations of sTREM-1	baseline

Outcome results